2 assets in Hereditary Amyloidosis

Therapeutic assets addressing Hereditary Amyloidosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Acoramidis Hereditary Amyloidosis	Eidos Therapeutics, a BridgeBio company	P3	B (60)
Nexiguran Ziclumeran Hereditary Amyloidosis	Intellia Therapeutics	P3	B (60)